160 related articles for article (PubMed ID: 37071060)
1. Spectrum of kinase gene rearrangements in a large series of paediatric inflammatory myofibroblastic tumours.
Preobrazhenskaya EV; Suleymanova AM; Bizin IV; Zagrebin FA; Romanko AA; Saitova ES; Mulkidzhan RS; Imyanitov EN
Histopathology; 2023 Jul; 83(1):109-115. PubMed ID: 37071060
[TBL] [Abstract][Full Text] [Related]
2. Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.
Antonescu CR; Suurmeijer AJ; Zhang L; Sung YS; Jungbluth AA; Travis WD; Al-Ahmadie H; Fletcher CD; Alaggio R
Am J Surg Pathol; 2015 Jul; 39(7):957-67. PubMed ID: 25723109
[TBL] [Abstract][Full Text] [Related]
3. Gene rearrangements in consecutive series of pediatric inflammatory myofibroblastic tumors.
Preobrazhenskaya EV; Iyevleva AG; Suleymanova AM; Tiurin VI; Mitiushkina NV; Bizin IV; Ivanstov AO; Gorustovich OA; Shelekhova KV; Kachanov DY; Varfolomeeva SR; Roschin VY; Kazakova AN; Litvinov DV; Shamanskaya TV; Savelov NA; Suspitsin EN; Imyanitov EN
Pediatr Blood Cancer; 2020 May; 67(5):e28220. PubMed ID: 32064735
[TBL] [Abstract][Full Text] [Related]
4. ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours.
Yamamoto H; Yoshida A; Taguchi K; Kohashi K; Hatanaka Y; Yamashita A; Mori D; Oda Y
Histopathology; 2016 Jul; 69(1):72-83. PubMed ID: 26647767
[TBL] [Abstract][Full Text] [Related]
5. Abdominal inflammatory myofibroblastic tumour: Clinicopathological and molecular analysis of 20 cases, highlighting potential therapeutic targets.
Vernemmen AIP; Samarska IV; Speel EM; Riedl RG; Goudkade D; de Bruïne AP; Wouda S; van Marion AM; Verlinden IV; van Lijnschoten I; Friederich P; Winnepenninckx VJL; Zur Hausen A; Sciot RME; van den Hout MFCM
Histopathology; 2024 Apr; 84(5):794-809. PubMed ID: 38155480
[TBL] [Abstract][Full Text] [Related]
6. Expanding the Molecular Characterization of Thoracic Inflammatory Myofibroblastic Tumors beyond ALK Gene Rearrangements.
Chang JC; Zhang L; Drilon AE; Chi P; Alaggio R; Borsu L; Benayed R; Travis WD; Ladanyi M; Antonescu CR
J Thorac Oncol; 2019 May; 14(5):825-834. PubMed ID: 30550870
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive evaluation of the test for 5'-/3'-end mRNA unbalanced expression as a screening tool for ALK and ROS1 fusions in lung cancer.
Mitiushkina NV; Romanko AA; Preobrazhenskaya EV; Tiurin VI; Ermachenkova TI; Martianov AS; Mulkidjan RS; Sokolova TN; Kholmatov MM; Bizin IV; Ivantsov AO; Yatsuk OS; Zaitseva OA; Iyevleva AG; Kuligina ES; Imyanitov EN
Cancer Med; 2022 Sep; 11(17):3226-3237. PubMed ID: 35322575
[TBL] [Abstract][Full Text] [Related]
8. Pseudosarcomatous myofibroblastic proliferations of the genitourinary tract are genetically different from nodular fasciitis and lack USP6, ROS1 and ETV6 gene rearrangements.
Jebastin JAS; Smith SC; Perry KD; Gupta NS; Alanee S; Carskadon S; Chitale DA; Palanisamy N; Williamson SR
Histopathology; 2018 Aug; 73(2):321-326. PubMed ID: 29617048
[TBL] [Abstract][Full Text] [Related]
9.
Mulkidjan RS; Saitova ES; Preobrazhenskaya EV; Asadulaeva KA; Bubnov MG; Otradnova EA; Terina DM; Shulga SS; Martynenko DE; Semina MV; Belogubova EV; Tiurin VI; Amankwah PS; Martianov AS; Imyanitov EN
Int J Mol Sci; 2023 Sep; 24(17):. PubMed ID: 37686416
[TBL] [Abstract][Full Text] [Related]
10. Inflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusions.
Lovly CM; Gupta A; Lipson D; Otto G; Brennan T; Chung CT; Borinstein SC; Ross JS; Stephens PJ; Miller VA; Coffin CM
Cancer Discov; 2014 Aug; 4(8):889-95. PubMed ID: 24875859
[TBL] [Abstract][Full Text] [Related]
11. Reclassification of a spindle cell sarcoma after identification of a TFG-ROS1 fusion: A case demonstrating the clinical benefit of next-generation sequencing in sarcoma.
Lim JJ; Chen EY; Schaub SK; Wagner MJ
Mol Genet Genomic Med; 2024 Apr; 12(4):e2423. PubMed ID: 38622850
[TBL] [Abstract][Full Text] [Related]
12. ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.
Zhao W; Choi YL; Song JY; Zhu Y; Xu Q; Zhang F; Jiang L; Cheng J; Zheng G; Mao M
Lung Cancer; 2016 Apr; 94():22-7. PubMed ID: 26973202
[TBL] [Abstract][Full Text] [Related]
13. Assessment of ALK Fusions in Uncommon Inflammatory Myofibroblastic Tumors With ALK IHC Positivity but FISH-Equivocal Findings by Targeted RNA Sequencing.
Yao Q; Bai Q; Zhang X; Ji G; Chang H; Cai X; Yu L; Wang J; Zhu X; Zhou X
Arch Pathol Lab Med; 2022 Oct; 146(10):1234-1242. PubMed ID: 35041745
[TBL] [Abstract][Full Text] [Related]
14. Histologic characterization of paediatric mesenchymal neoplasms treated with kinase-targeted therapy.
Baranov E; Winsnes K; O'Brien M; Voss SD; Church AJ; Janeway KA; DuBois SG; Davis JL; Al-Ibraheemi A
Histopathology; 2022 Aug; 81(2):215-227. PubMed ID: 35543076
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive analysis of
Zhou C; Li M; Guo Z; Li K; Zhai X; Xie Y; Yang X; Wu Y; Xiao W; Xu W
J Genet; 2020; 99():. PubMed ID: 33168793
[TBL] [Abstract][Full Text] [Related]
16. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review.
Zhang L; Luan L; Shen L; Xue R; Huang J; Su J; Huang Y; Xu Y; Wang X; Shao Y; Ji Y; Xu C; Hou Y
Virchows Arch; 2023 Mar; 482(3):567-580. PubMed ID: 36624188
[TBL] [Abstract][Full Text] [Related]
17. ROS1 and ALK fusions in colorectal cancer, with evidence of intratumoral heterogeneity for molecular drivers.
Aisner DL; Nguyen TT; Paskulin DD; Le AT; Haney J; Schulte N; Chionh F; Hardingham J; Mariadason J; Tebbutt N; Doebele RC; Weickhardt AJ; Varella-Garcia M
Mol Cancer Res; 2014 Jan; 12(1):111-8. PubMed ID: 24296758
[TBL] [Abstract][Full Text] [Related]
18. Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor.
Cools J; Wlodarska I; Somers R; Mentens N; Pedeutour F; Maes B; De Wolf-Peeters C; Pauwels P; Hagemeijer A; Marynen P
Genes Chromosomes Cancer; 2002 Aug; 34(4):354-62. PubMed ID: 12112524
[TBL] [Abstract][Full Text] [Related]
19. Multiplex fluorescence in situ hybridisation to detect anaplastic lymphoma kinase and ROS proto-oncogene 1 receptor tyrosine kinase rearrangements in lung cancer cytological samples.
Zito Marino F; Rossi G; Cozzolino I; Montella M; Micheli M; Bogina G; Munari E; Brunelli M; Franco R
J Clin Pathol; 2020 Feb; 73(2):96-101. PubMed ID: 31562206
[TBL] [Abstract][Full Text] [Related]
20. Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma.
Piton N; Ruminy P; Gravet C; Marchand V; Colasse É; Lamy A; Naoures Mear CL; Bibeau F; Marguet F; Guisier F; Salaün M; Thiberville L; Jardin F; Sabourin JC
Lab Invest; 2018 Mar; 98(3):371-379. PubMed ID: 29251734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
